RA
BIO icon

RFG Advisory’s Bio-Rad Laboratories Class A BIO Stock Holding History

RFG Advisory’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-773
Closed -$277K – 649
2023
Q3 		$277K Sell
773
-37
-5% -$14.3K 0.01% 527
2023
Q2 		$307K Sell
810
-2
-0.2% -$814 0.01% 520
2023
Q1 		$389K Sell
812
-11
-1% -$5.15K 0.02% 461
2022
Q4 		$388K Buy
823
+99
+14% +$40K 0.02% 462
2022
Q3 		$277K Buy
724
+70
+11% +$34.9K 0.02% 503
2022
Q2 		$353K Sell
654
-28
-4% -$14.6K 0.02% 428
2022
Q1 		$384K Buy
682
+79
+13% +$47.6K 0.02% 375
2021
Q4 		$456K Sell
603
-71
-11% -$53.1K 0.03% 321
2021
Q3 		$503K Sell
674
-101
-13% -$75.7K 0.04% 273
2021
Q2 		$499K Sell
775
-20
-3% -$12.2K 0.04% 267
2021
Q1 		$454K Sell
795
-7
-0.9% -$4.14K 0.05% 271
2020
Q4 		$498K Sell
802
-64
-7% -$36.4K 0.07% 246
2020
Q3 		$446K Buy
866
+68
+9% +$34.4K 0.06% 246
2020
Q2 		$360K Buy
798
+136
+21% +$60K 0.06% 253
2020
Q1 		$232K Buy
+662
New +$243K 0.04% 300

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RFG Advisory's BIO Position: Q4 2023 in Review

RFG Advisory sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2023, closing a stake of 773 shares — an estimated $277K sold.

RFG Advisory first reported a position in BIO in Q1 2020 and held it in 15 quarters. The position peaked at $503K in Q3 2021. 484 funds tracked by Wall St. Rank hold BIO as of Q4 2023.

  • RFG Advisory reported no remaining Bio-Rad Laboratories Class A position as of Q4 2023 after selling out during the quarter.
  • RFG Advisory sold 773 Bio-Rad Laboratories Class A shares in Q4 2023, an estimated $277K.
  • RFG Advisory first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 15 quarters.
  • RFG Advisory's Bio-Rad Laboratories Class A position peaked at $503K in Q3 2021.
  • 484 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2023.

Based on RFG Advisory's 13F filing for Q4 2023, filed 25 Jan 2024.